These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Fiskus W; Mill CP; Nabet B; Perera D; Birdwell C; Manshouri T; Lara B; Kadia TM; DiNardo C; Takahashi K; Daver N; Bose P; Masarova L; Pemmaraju N; Kornblau S; Borthakur G; Montalban-Bravo G; Manero GG; Sharma S; Stubbs M; Su X; Green MR; Coarfa C; Verstovsek S; Khoury JD; Vakoc CR; Bhalla KN Blood Cancer J; 2021 May; 11(5):98. PubMed ID: 34016956 [TBL] [Abstract][Full Text] [Related]
4. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Saenz DT; Fiskus W; Manshouri T; Rajapakshe K; Krieger S; Sun B; Mill CP; DiNardo C; Pemmaraju N; Kadia T; Parmar S; Sharma S; Coarfa C; Qiu P; Verstovsek S; Bhalla KN Leukemia; 2017 Mar; 31(3):678-687. PubMed ID: 27677740 [TBL] [Abstract][Full Text] [Related]
5. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144 [TBL] [Abstract][Full Text] [Related]
6. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946 [TBL] [Abstract][Full Text] [Related]
7. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522 [TBL] [Abstract][Full Text] [Related]
8. Transcription Factor 7-like 2 Mediates Canonical Wnt/β-Catenin Signaling and c-Myc Upregulation in Heart Failure. Hou N; Ye B; Li X; Margulies KB; Xu H; Wang X; Li F Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301468 [TBL] [Abstract][Full Text] [Related]
9. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532 [TBL] [Abstract][Full Text] [Related]
11. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis. Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402 [TBL] [Abstract][Full Text] [Related]
12. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Fiskus W; Sharma S; Saha S; Shah B; Devaraj SG; Sun B; Horrigan S; Leveque C; Zu Y; Iyer S; Bhalla KN Leukemia; 2015 Jun; 29(6):1267-78. PubMed ID: 25482131 [TBL] [Abstract][Full Text] [Related]
13. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Fiskus W; Cai T; DiNardo CD; Kornblau SM; Borthakur G; Kadia TM; Pemmaraju N; Bose P; Masarova L; Rajapakshe K; Perera D; Coarfa C; Mill CP; Saenz DT; Saenz DN; Sun B; Khoury JD; Shen Y; Konopleva M; Bhalla KN Blood Cancer J; 2019 Jan; 9(2):4. PubMed ID: 30647404 [TBL] [Abstract][Full Text] [Related]
14. Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia. Monteith AJ; Ramsey HE; Silver AJ; Brown D; Greenwood D; Smith BN; Wise AD; Liu J; Olmstead SD; Watke J; Arrate MP; Gorska AE; Fuller L; Locasale JW; Stubbs MC; Rathmell JC; Savona MR Cancer Res; 2024 Apr; 84(7):1101-1114. PubMed ID: 38285895 [TBL] [Abstract][Full Text] [Related]
15. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878 [TBL] [Abstract][Full Text] [Related]
16. BRD4-mediated repression of p53 is a target for combination therapy in AML. Latif AL; Newcombe A; Li S; Gilroy K; Robertson NA; Lei X; Stewart HJS; Cole J; Terradas MT; Rishi L; McGarry L; McKeeve C; Reid C; Clark W; Campos J; Kirschner K; Davis A; Lopez J; Sakamaki JI; Morton JP; Ryan KM; Tait SWG; Abraham SA; Holyoake T; Higgins B; Huang X; Blyth K; Copland M; Chevassut TJT; Keeshan K; Adams PD Nat Commun; 2021 Jan; 12(1):241. PubMed ID: 33431824 [TBL] [Abstract][Full Text] [Related]
17. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS; Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663 [No Abstract] [Full Text] [Related]
18. A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells. Guo L; Li J; Zeng H; Guzman AG; Li T; Lee M; Zhou Y; Goodell MA; Stephan C; Davies PJA; Dawson MA; Sun D; Huang Y Nat Commun; 2020 Feb; 11(1):740. PubMed ID: 32029739 [TBL] [Abstract][Full Text] [Related]
20. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes. Ma L; Wang J; Zhang Y; Fang F; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Sang X; Zhang K; Lu L; Wan X; Chen Y; Yu J; Zhuo R; Wu S; Lu J; Pan J; Hu S Cancer Biol Ther; 2022 Dec; 23(1):1-15. PubMed ID: 36170346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]